Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: An asexual blood-stage vaccine for Plasmodium falciparum malaria

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Mullen, Gregory E D ^a   Ellis, Ruth D ^a   Miura, Kazutoyo ^a   Malkin, Elissa ^b   Nolan, Caroline ^c   Hay, Mhorag ^c   Fay, Michael P ^a   Saul, Allan ^d   Zhu, Daming ^a   Rausch, Kelly ^a   Moretz, Samuel ^a   Zhou, Hong ^a   Long, Carole A ^a   Miller, Louis H ^a   Treanor, John ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PATH Malaria Vaccine Initiative   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1 PLUS ALUMINUM HYDROXIDE; CPG 7909; IMMUNOGLOBULIN G; MALARIA VACCINE; VAXIMMUNE; AGATOLIMOD; ALUMINUM HYDROXIDE; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; MEMBRANE PROTEIN; OLIGODEOXYRIBONUCLEOTIDE; PARASITE ANTIGEN; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG;

ACNE; ADULT; ANOREXIA; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; ASEXUAL REPRODUCTION; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGASTRIC PAIN; ERYTHEMA; FATIGUE; FEVER; FOLLICULITIS; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; INJECTION SITE INDURATION; LEUKOPENIA; MACULOPAPULAR RASH; MALARIA; MALARIA CONTROL; MONOTHERAPY; MYALGIA; NORMAL HUMAN; OCULAR PRURITUS; PAIN; PAPULAR RASH; PARASITE CONTROL; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; TEMPERATURE; THORAX PAIN; THROMBOCYTOPENIA; UNITED STATES; VACCINATION; VOMITING; ADOLESCENT; ANIMAL; IMMUNOLOGY; MALARIA FALCIPARUM; MIDDLE AGED; SAFETY;

PLASMODIUM FALCIPARUM;

ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANIMALS; ANTIGENS, PROTOZOAN; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SAFETY;

EID: 51449101218     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002940     Document Type: Article

References (35)

1. WHO (2005) World Malaria Report, World Health Organization.
2. Anders RF, Crewther PE, Edwards S, Margetts M, Matthew ML, et al. (1998) Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16: 240-247.
3. Narum DL, Ogun SA, Thomas AW, Holder AA (2000) Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun 68: 2899-2906.
4. Deans JA, Knight AM, Jean WC, Waters AP, Cohen S, et al. (1988) Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD Merozoite antigen. Parasite Immunol 10: 535-552.
5. Collins WE, Pye D, Crewther PE, Vandenberg KL, Galland GG, et al. (1994) Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 51: 711-719.
6. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, et al. (2002) Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 70: 6961-6967.
7. Marshall VM, Zhang L, Anders RF, Coppel RL (1996) Diversity of the vaccine candidate AMA-1 of Plasmodium falciparum. Mol Biochem Parasitol 77: 109-113.
8. Polley SD, Conway DJ (2001) Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics 158: 1505-1512.
9. Escalante AA, Grebert HM, Chaiyaroj SC, Magris M, Biswas S, et al. (2001) Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum. X. Asembo Bay Cohort Project. Mol Biochem Parasitol 113: 279-287.
10. Healer J, Crawford S, Ralph S, McFadden G, Cowman AF (2002) Independent translocation of two micronemal proteins in developing Plasmodium falciparum merozoites. Infect Immun 70: 5751-5758.
11. Remarque EJ, Faber BW, Kocken CH, Thomas AW (2008) Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24: 74-84.
12. Dutta S, Lee SY, Batchelor AH, Lanar DE (2007) Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A 104: 12488-12493.
13. Duan S, Mu J, Thera M, Joy D, Kosakovsky Pond S, et al. (2008) Population structure of the genes encoding the polymorphic P. falciparum apical membrane antigen1: implications for vaccine design. Proc Natl Acad Sci U S A, In Press.
14. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, et al. (2002) In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70: 6948-6960.
15. Remarque EJ, Faber BW, Kocken CH, Thomas AW (2008) A diversity-covering approach to immunisation with Plasmodium falciparum AMA1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun.
16. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, et al. (2005) Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 73: 3677-3685.
17. Dicko A, Diemert DJ, Sagara I, Sogoba M, Niambele MB, et al. (2007) Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians . PLoS ONE 2: e1045.
18. Dicko A, Sagara I, Ellis R, Miura K, Guindo O, et al. (2008) Phase 1 Study of a Combination AMA1 Blood Stage Malaria Vaccine in Malian Children. PLoS ONE 3: e1563.
19. ClinicalTrials.gov (2006) www.ClinicalTrials.gov, ClinicalTrials.gov Identifier: NCT00341250, Randomized, Controlled, Phase 1/2 Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel Vaccine for Plasmodium Falciparum Malaria in Children in Doneguebougou and Bancoumana, Mali.
20. Epstein JE, Giersing B, Mullen G, Moorthy V, Richie TL (2007) Malaria vaccines: are we getting closer? Curr Opin Mol Ther 9: 12-24.
21. Girard MP, Reed ZH, Friede M, Kieny MP (2007) A review of human vaccine research and development: malaria. Vaccine 25: 1567-1580.
22. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, et al. (2005) CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. Aids 19: 1473-1479.
23. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, et al. (2004) CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24: 693-701.
24. Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, et al. (2004) Safety and immunogenicity or CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22: 3136-3143.
25. Klinman DM (2006) CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine. Expert Rev Vaccines 5: 365-369.
26. Mullen GE, Giersing BK, Ajose-Popoola O, Davis HL, Kothe C, et al. (2006) Enhancement of functional antibody responses to AMA1-C1/ Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24: 2497-2505.
27. Mullen GE, Aebig JA, Dobrescu G, Rausch K, Lambert L, et al. (2007) Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. Vaccine 25: 5343-5347.
28. Aebig JA, Mullen GE, Dobrescu G, Rausch K, Lambert L, et al. (2007) Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods 323: 139-146.
29. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, et al. (2008) Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26: 193-200.
30. Campbell G, Skillings J (1985) Nonparametric stepwise multiple comparison procedures. Journal of the American Statistical Association 80: 998-1003.
31. Team RDC (2007) R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing.
32. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL (2004) Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration or CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 27: 460-471.
33. van der Spuy ZM, Dyer SJ (2004) The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18: 755-771.
34. Shmerling RH, Delbanco TL (1991) The rheumatoid factor: an analysis of clinical utility. Am J Med 91: 528-534.
35. Keren DF (2002) Antinuclear antibody testing. Clin Lab Med 22: 447-474.